Free Trial

Canopy Growth (CGC) Stock Forecast & Price Target

Canopy Growth logo
$4.23 -0.32 (-7.03%)
(As of 03:58 PM ET)

Canopy Growth - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
2
Buy
0

Based on 3 Wall Street analysts who have issued ratings for Canopy Growth in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 3 analysts, 1 has given a sell rating, and 2 have given a hold rating for CGC.

Consensus Price Target

$3.50
-17.26% Downside
According to the 3 analysts' twelve-month price targets for Canopy Growth, the average price target is $3.50. The highest price target for CGC is $5.00, while the lowest price target for CGC is $2.00. The average price target represents a forecasted downside of -17.26% from the current price of $4.23.
Get the Latest News and Ratings for CGC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Canopy Growth and its competitors.

Sign Up

CGC Analyst Ratings Over Time

TypeCurrent Forecast
11/9/23 to 11/8/24
1 Month Ago
10/10/23 to 10/9/24
3 Months Ago
8/11/23 to 8/10/24
1 Year Ago
11/9/22 to 11/9/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
1 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$3.50$3.50$4.53$16.20
Forecasted Upside-17.26% Downside-13.15% Downside-28.83% Downside209.75% Upside
Consensus Rating
Reduce
Reduce
Reduce
Hold

CGC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CGC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Canopy Growth Stock vs. The Competition

TypeCanopy GrowthMedical CompaniesS&P 500
Consensus Rating Score
1.67
2.80
2.50
Consensus RatingReduceModerate BuyHold
Predicted Upside-23.08% Downside9,981.51% Upside7.42% Upside
News Sentiment Rating
Positive News

See Recent CGC News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/9/2024Piper Sandler
2 of 5 stars
 Lower TargetUnderweight ➝ Underweight$3.00 ➝ $2.00-68.05%
6/17/2024Atb Cap Markets
5 of 5 stars
F. Gomes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
1/31/2024Sanford C. Bernstein
3 of 5 stars
 Boost TargetMarket Perform$5.00+3.31%
9/15/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderperform ➝ Underperform$5.60 ➝ $6.60-51.18%
5/1/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform
2/17/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$33.00 ➝ $32.00+27.49%
2/13/2023Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
W. Kirk
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
2/10/2023CIBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetC$25.00 ➝ C$17.50
2/9/2023Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetC$45.00 ➝ C$35.00

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 04:02 PM ET.


CGC Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Canopy Growth is $3.50, with a high forecast of $5.00 and a low forecast of $2.00.

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Canopy Growth in the last year. There is currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" CGC shares.

According to analysts, Canopy Growth's stock has a predicted downside of -17.26% based on their 12-month stock forecasts.

Analysts like Canopy Growth less than other "medical" companies. The consensus rating for Canopy Growth is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CGC compares to other companies.


This page (NASDAQ:CGC) was last updated on 11/8/2024 by MarketBeat.com Staff
From Our Partners